Cloud med
⚡Tap Here To Unlock Exclusive Savings at Cloud Medication.com
⚡ Shop Today & Enjoy Up To 25% OFF + Fast Priority Processing Cloud Medication.com
⚡ Easy Checkout • Premium Quality • Limited-Time Deals Live Now
Opana ER 30mg: Extended-Release Pain Relief Medication Overview Guide
Introduction
Opana ER 30mg was a prescription extended-release opioid medication used for the management of severe chronic pain requiring continuous, around-the-clock treatment. The active ingredient is oxymorphone, a potent opioid analgesic designed to provide long-lasting pain control.
Although historically used in clinical settings, Opana ER has been removed from the U.S. market, primarily due to serious safety and public health concerns related to misuse and adverse outcomes.
This guide provides an educational overview of how Opana ER worked, its medical use, safety profile, and why it is no longer widely available.
What Is Opana ER (Oxymorphone)?
Opana ER contained oxymorphone hydrochloride, a semi-synthetic opioid derived from thebaine. It was formulated as an extended-release tablet designed to release medication slowly over time.
Key characteristics:
Drug class: Strong opioid analgesic
Formulation: Extended-release (ER)
Intended use: Continuous severe pain management
Schedule: Controlled substance (high abuse potential)
According to FDA documentation, oxymorphone ER was indicated only when alternative treatments were inadequate for severe pain requiring long-term opioid therapy.
How Did Opana ER Work?
Opana ER worked by binding to opioid receptors in the brain and spinal cord, which are responsible for pain signaling.
Effects included:
Reduced perception of pain
Altered emotional response to pain
Sedation and relaxation
Slowed transmission of pain signals
Because it was extended-release, the medication was designed to provide steady pain relief over many hours rather than immediate short-term relief.
Common Medical Uses
When it was prescribed, Opana ER was used for:
Severe Chronic Pain
Long-term pain conditions requiring continuous opioid therapy.
Cancer-Related Pain
Used in palliative care settings when other treatments were insufficient.
Around-the-Clock Pain Management
Reserved for patients requiring consistent, long-acting pain control.
FDA guidance emphasized that it should only be used when non-opioid options were inadequate.
Dosage Form (Opana ER 30mg)
30mg Extended-Release Tablets
High-strength opioid formulation
Designed for opioid-tolerant patients
Not intended for mild or occasional pain
Taken on a fixed dosing schedule
Important clinical note: ER opioids must be swallowed whole and not altered in any way, as this can release a potentially dangerous dose at once.
Comparison Table: Opana ER vs Other Opioids
FeatureOpana ER (Oxymorphone)Oxycodone ERMorphine ER| Potency | Very high | High | Moderate |
| Duration | Long-acting | Long-acting | Long-acting |
| Use | Severe chronic pain | Moderate–severe pain | Moderate–severe pain |
| Risk Level | Very high | High | Moderate |
| Availability | Discontinued in U.S. | Available | Available |
Important Safety Considerations
Opana ER carried significant risks, which contributed to its removal from the U.S. market.
1. Respiratory Depression
One of the most serious risks was slowed or stopped breathing, especially at higher doses or when combined with other depressants.
2. Sedation and Cognitive Impairment
Common effects included:
Drowsiness
Confusion
Dizziness
Reduced alertness
3. Dependence and Addiction Risk
Like all strong opioids, oxymorphone carried a high risk of:
Physical dependence
Tolerance
Misuse and addiction
4. Dangerous Drug Interactions
Risk increased significantly when combined with:
Alcohol
Benzodiazepines
Other CNS depressants
These combinations could lead to life-threatening respiratory failure.
Why Opana ER Was Removed
Regulatory agencies determined that the risks outweighed the benefits after widespread reports of serious harm linked to misuse.
Key concerns included:
High abuse potential
Severe complications when misused
Public health risks associated with injection misuse
Outbreaks of infectious diseases linked to unsafe use practices
As a result, the manufacturer voluntarily removed the product from the U.S. market following FDA action.
Possible Side Effects (Historical Use)
Common Side Effects
Constipation
Nausea
Drowsiness
Dizziness
Dry mouth
Serious Side Effects
Respiratory depression
Severe sedation
Loss of consciousness
Low blood pressure
Storage Information (When It Was Available)
Store at room temperature
Keep securely locked away
Protect from moisture and heat
Keep away from children and pets
Safe Pain Management Alternatives
In modern clinical practice, chronic pain management often uses a combination of:
Non-opioid analgesics (NSAIDs, acetaminophen)
Physical therapy
Nerve-targeting medications
Interventional pain procedures
Safer opioid alternatives when necessary
Frequently Asked Questions
What was Opana ER used for?
It was used for severe chronic pain requiring continuous opioid therapy.
Is Opana ER still available?
No. It has been removed from the U.S. market.
Was Opana ER strong?
Yes. It was considered a very high-potency opioid medication.
Why was it discontinued?
Due to safety concerns and high potential for misuse and harm.
What replaced Opana ER?
Doctors typically use other opioid or non-opioid pain management strategies depending on the patient.
Conclusion
Opana ER 30mg (oxymorphone extended-release) was a powerful opioid used for severe chronic pain management. While effective in controlled medical settings, it carried significant risks including respiratory depression, dependence, and serious public health concerns.
Due to these risks, it was removed from the U.S. market, and safer pain management alternatives are now preferred in modern clinical practice.
Educational understanding of such medications helps highlight the importance of careful opioid use, medical supervision, and safer pain management strategies.